"We need more data on the long-term effects and other outcomes related to cardiovascular health, particularly in lower-risk individuals," says Eva Madrid, co-lead researcher from the Universidad de Valparaso, Chile
Similar benefits have also been demonstrated in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) [10, 11]
This decision helps to preserve coverage for other lifesaving procedures and treatment options for the 5.2 million people who count on their Blue Cross health coverage
Thomsen RW, Mailhac A, Lohde JB, Pottegard A
Burrin DG, Stoll B, Jiang R, Petersen Y, Elnif J, Buddington RK, et al
For companies such as Sandoz, this nevertheless presents an opportunity to gain initial experience and secure market share